Trump Administration Bars Medicaid and CHIP From Covering Transgender Care for Minors
The Trump administration finalized a rule on August 11, 2026, that bars Medicaid and the Children's Health Insurance Program (CHIP) from covering puberty blockers, hormone treatments, and surgeries for transgender minors. The prohibition takes effect October 12, 2026 (The Hill).
Medicaid and CHIP are joint federal-state programs that provide health coverage to low-income Americans and children. The rule, proposed in December 2025 by the Department of Health and Human Services, prohibits federal funds from being used to pay for gender-affirming care for children covered by either program (NPR).
CMS Administrator Dr. Mehmet Oz issued a statement to state Medicaid agencies directing that Medicaid dollars are not to be used for gender reassignment surgeries or hormone treatments in minors, a position he first communicated in April 2025 (CMS).
Oz explained CMS's reasoning in a social media video, stating that when the harms of sex-rejecting procedures are serious and the evidence is weak, the government cannot keep signing the checks (NPR). He said the rule will protect children from "irreversible harm" (Healthcare Dive).
Katie Keith, director of the Center for Health Policy and the Law at Georgetown, said she is not aware of any other time the federal government has prohibited federal funds in this way for a specific patient population with a particular diagnosis. She called the rule unprecedented and untested (NPR).
KFF, a health research organization, estimates there are 130,000 transgender people under age 18 living in states where gender-affirming care is still available (NPR).
The finalization follows a series of incremental steps by the administration. In December 2025, HHS proposed new restrictions designed to block access to gender-affirming care for minors (AP News). In early January 2026, the administration agreed not to issue notices of exclusion from Medicare or Medicaid to providers offering gender-affirming care, delaying those provider exclusions (Reuters). On March 10, 2026, a U.S. appeals court upheld West Virginia's ban on Medicaid coverage for gender-affirming surgeries (Reuters).
The administration's approach is a reversal from the prior administration's posture. A 2021 Biden-Harris CMS press release announced approval of Colorado's essential health benefits benchmark plan changes expanding coverage of LGBTQ care, including additional services for transgender individuals (CMS).
The federal rule operates alongside existing Medicare policy. According to CMS's Medicare Coverage Database, local Medicare Administrative Contractors (MACs) determine coverage of gender reassignment surgery on a case-by-case basis (CMS).
For state Medicaid directors and CMS regional offices, the implementation window between finalization and the October 12 effective date is narrow. State agencies will need to update coverage policies, beneficiary notices, and provider communications before the prohibition takes hold. States where gender-affirming care remains legal will still lose federal matching funds for those services under the rule, creating a gap between what states may permit under their own law and what the federal government will help pay for.
The broader context here is that Keith's characterization of the rule as untested signals likely litigation. Advocacy groups have challenged state-level restrictions on similar constitutional and statutory grounds, and the federal prohibition's targeting of a specific diagnosis and patient population, rather than a broad benefit category, raises novel questions under the Medicaid Act's coverage requirements. The March appeals court ruling upholding West Virginia's Medicaid exclusion provides a favorable precedent for the administration, but federal courts have not yet ruled on a nationwide prohibition of this scope.
